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Recently, two studies have claimed that cholesterol
lowering drugs, particularly statins, protect against age
related maculopathy.1 2 The end stage of this progres›
sive retinal disorder is the commonest cause of
untreatable blindness in elderly people in Western
societies, and its prevalence is expected to rise with the
ageing of the population. Thus, preventing this
disorder would have an enormous public health
impact.3 The above mentioned studies used interview
data on drug use and had a low statistical power. We
therefore tested the hypothesis that cholesterol
lowering drugs protect against age related maculo›
pathy in a large cohort study with cumulative exposure
measured.
Participants, methods, and results
This investigation was part of the Rotterdam study, a
population based cohort study of people aged 55
years and more. After the baseline phase from 1990 to
1993, two follow up examinations were performed at
mean intervals of 2 and 6.5 years. Of all the subjects at
risk of age related maculopathy, 4822 (83%)
participated at follow up. A diagnosis of age related
maculopathy was based on stereoscopic colour fundus
transparencies graded according to the international
classification system.4 The incidence of the disorder
was defined as the development of soft distinct drusen
with pigmentary irregularities, indistinct drusen, or
the end stages of atrophic or neovascular age related
macular degeneration.
A register of prescriptions filled by local pharma›
cies provided continuous data on use of cholesterol
lowering drugs. These data were available for 99% of
the cohort from 1 January 1991 onwards. We used Cox
proportional hazards regression analysis to calculate
hazard ratios, with age in days as the time axis to ensure
optimal controlling for age. Cumulative exposure to
drugs was represented as a time dependent covariate
and was analysed both as a dichotomous and a
categorical variable. The model compared each
incident case of age related maculopathy with all
subjects in the cohort who were alive and free of the
disorder at the age when the case of maculopathy was
diagnosed.5
During 26 781 person years of follow up, 457
patients used cholesterol lowering drugs for one or
more days, and 419 cases of incident age related macu›
lopathy were observed. Use of cholesterol lowering
drugs at any time, defined as a binary variable, was not
associated with the incidence of age related maculo›
pathy (hazard ratio 1.0 (95% confidence interval 0.7 to
1.5)). Compared with patients who had never used
cholesterol lowering drugs, cumulative exposure for
less than one month, for one month to a year, or for
more than a year did not have a protective effect on the
risk of maculopathy (see table). Additional adjustment
for body mass index, hypertension, smoking, and
peripheral arterial disease (ankle:arm index < 0.9) did
not change the association. When we performed the
same analysis with progression of age related
maculopathy as the outcome variable, we obtained the
same results.
Comment
Exposure to cholesterol lowering drugs did not change
patients’ risk of age related maculopathy. In contrast
with the studies that reported a protective effect, we
used a prospective design and assessed drug use by
means of data registered by pharmacies. This
minimised potential selection and information bias,
and our data provided quantitative information for
each patient’s cumulative exposure to drugs. This pre›
vented misclassification of the duration of drug use.
Even though the total number of participants was high,
the number of subjects using cholesterol lowering
drugs who developed age related maculopathy was
low, possibly leading to a type II error. With a two sided
á of 0.05, we had a power of 80% to show a relative risk
of 0.7 or lower. The fact that we did not find an associ›
ation between cholesterol lowering drugs and age
related maculopathy makes a protective effect of statins
unlikely.
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Hazard ratios of age related maculopathy (ARM) associated with the use of cholesterol
lowering drugs
Exposure to
cholesterol lowering
drugs
No of subjects
with incident
ARM (n=419)
No of subjects in
total cohort
(n=4822)
Crude hazard
ratio (95% CI)*
Adjusted hazard
ratio (95% CI)†
All drugs:
No exposure‡ 391 4365 1.0 1.0
<1 month 2 26 1.1 (0.3 to 4.3) 1.2 (0.3 to 5.0)
1›<12 months 8 136 1.0 (0.5 to 2.1) 1.0 (0.5 to 2.0)
>12 months 18 295 1.0 (0.6 to 1.6) 1.2 (0.7 to 1.9)
Statins:
No exposure‡ 394 4407 1.0 1.0
<1 month 2 21 1.5 (0.4 to 6.1) 1.6 (0.4 to 6.5)
1›<12 months 7 120 1.0 (0.5 to 2.1) 0.9 (0.4 to 2.1)
>12 months 16 274 1.0 (0.6 to 1.6) 1.1 (0.7 to 1.9)
*Adjusted for age and sex.
†Additional adjustment for body mass index, smoking, hypertension, and peripheral arterial disease.
‡In this time dependent analysis, cumulative drug exposure of each case was compared with that for all
other subjects in the cohort as controls, on the index date half way between the two examinations when the
incident case occurred. Controls may contribute more than once. Hence, relative risks cannot be calculated
with the numbers given in the table.
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Mortality from cardiovascular disease more than 10 years
after radiotherapy for breast cancer: nationwide cohort
study of 90 000 Swedish women
During radiotherapy for breast cancer there is often
some irradiation of the heart and major blood vessels,
which could increase cardiovascular mortality many
years later.1–3 The dose of radiation to the heart is
generally higher when the left rather than the right
breast is affected. Therefore, indirect evidence on the
magnitude of any risk is available where the tumour
laterality (left or right breast) can be linked to
subsequent cardiovascular mortality.1 2 Studies of the
survivors of the atomic bombing of Japan who
received single doses to the whole body of 0›4 Gy
show that the cardiovascular disease risk is dose
related and increases by about 14% per gray.4
Participants, methods, and results
Since 1970, the nationwide Swedish cancer registry
has recorded the laterality of breast cancers but not
the use of radiotherapy. Unpublished data from
regional Swedish registries suggest that about 30% of
women with early breast cancer during the 1970s and
early ’80s received radiotherapy. We linked registry
records (1970›96) with national mortality records. The
study was approved by the ethics committee of the
Karolinska Institute.
After we excluded women whose cancer was
diagnosed at autopsy or outside Sweden and those
with previously registered cancers (except squamous
cell skin cancer), 89 407 women aged 18›79 with
unilateral breast cancer remained. We stratified
analyses of subsequent mortality in groups of five
years by calendar year of diagnosis, time since
diagnosis, and age at diagnosis. Stratification by age
was necessary because the proportion of left sided
tumours increases with age.5 Each woman’s
contribution to the person years at risk ran from the
date of diagnosis until her date of death, date of
emigration, 100th birthday, or 1 January 1997,
whichever was earliest. We used Poisson regression to
calculate mortality ratios, left versus right, from the
numbers of deaths and person years. Ratios greater
than one indicate greater mortality in women with left
sided tumours than in women with right sided
tumours.
Mortality from breast cancer was identical in
women with left sided or right sided tumours (table).
Mortality from cardiovascular diseases was higher in
women with left sided tumours. Little excess occurred
in the first 10 years after diagnosis (mortality ratio
1.01; 95% confidence interval 0.96 to 1.07), but later
the ratio was 1.10 (1.03 to 1.18; P=0.004), 1.13 (1.03 to
1.25; P=0.01) for ischaemic heart disease (half of all
cardiovascular mortality), and 1.08 (0.98 to 1.18) for
other cardiovascular deaths (about 30% of which
Mortality ratio for women with left sided breast cancer versus women with right sided breast cancer during and after the first 10 years
from diagnosis of breast cancer among 89 407 women registered during 1970›96 at the Swedish cancer registry
Cause of death (ICD›9 code)
All years <10 years >10 years
Mortality ratio, left
versus right (95% CI)
No of
deaths
Mortality ratio, left
versus right (95% CI)
No of
deaths
Mortality ratio, left
versus right (95% CI)
Breast cancer (174) 1.00 (0.98 to 1.03) 21 196 1.00 (0.97 to 1.03) 2714 1.00 (0.93 to 1.08)
Cardiovascular diseases:
All (390›459, 785, and 798) 1.04 (1.00 to 1.09)* 5 739 1.01 (0.96 to 1.07) 3426 1.10 (1.03 to 1.18)†
Ischaemic heart disease (410›414) 1.06 (1.00 to 1.12)‡ 3 078 1.02 (0.95 to 1.10) 1613 1.13 (1.03 to 1.25)§
Other cardiovascular diseases 1.03 (0.97 to 1.09) 2 661 1.00 (0.93 to 1.08) 1813 1.08 (0.98 to 1.18)
Remaining causes 0.97 (0.93 to 1.02) 4 446 0.96 (0.90 to 1.01) 2602 1.00 (0.92 to 1.07)
ICD›9=International classification of diseases, ninth revision.
*P=0.04
†P=0.004
‡P=0.05
§P=0.01
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